Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggeredSignificant events, October-December • Alligator Bioscience recorded a revenue of USD 6 million from Janssen, coupled to a decision to start combination study with ADC-1013/JNJ-64457107. This milestone payment was received in January 2018. • A decision was taken to expand the management team with Chief Medical Officer Charlotte A Russell, MD, PhD and Vice President Discovery Peter Ellmark, Associate Professor. • Results from Alligator Bioscience’s clinical Phase I study presented, supporting a continued